17 years ago, Zhang et al. demonstrated that animals carrying a single knockout allele of Kras were considerably more sensitive than wild-type (WT) animals to the induction of chemically induced lung tumors (Zhang et al., 2001) . They also found that ectopic expression of WT K-Ras4B-an isoform named for its use of an alternative fourth exon in the Kras gene and having a different C terminus, and thus membrane anchoring, than K-Ras4A-suppressed growth and reduced mitogen-activated protein kinase (MAPK) signaling in cultured cells (Zhang et al., 2001) , suggesting for the first time a functional interplay between mutant and WT K-Ras. In their Cell paper, Ambrogio and colleagues (2018) revisit the idea of K-Ras as a growth suppressor by generating animals carrying both conditional knockout and conditional activated alleles of Kras and demonstrating that Cre-induced lung tumors expressing mutant K-Ras grow faster when the WT allele is deleted. Interestingly, analogous experiments in hematopoietic cells demonstrated that WT K-Ras suppresses the oncogenic activity of the mutant, but WT N-Ras does not do the same for its mutant counterpart (Kong et al., 2016; Xu et al., 2013) .
How does the WT form of an oncoprotein suppress the activity of the mutant? The mechanism of growth suppression by WT K-Ras has not been firmly established, but might involve distinct signaling properties of WT and mutant or dimerization of the WT and mutant forms (Burgess et al., 2017; Zhang et al., 2001) . The idea that K-Ras signals as a dimer or higherorder oligomer has been gaining traction, partly due to the evidence that one of its major effectors, RAF, requires heterodimerization for activation of downstream signaling. The most compelling evidence for K-Ras dimerization comes from highresolution microscopy studies, which suggest that the oncogenic mutant K-Ras4B G12D forms dimers and oligomers as its concentration increases in cells and that MAPK signaling is not activated until K-Ras4B G12D reaches a concentration that promotes dimerization (Nan et al., 2015) . Nuclear-magnetic-resonance (NMR)-based structural studies revealed that guanosine triphosphate (GTP)-bound, but not guanosine diphosphate (GDP)-bound, K-Ras4B can form stable homodimers in solution, with one dimer interface encompassing the effector interaction domain (switch I) and the other encompassing the a3-a4 helical region of the allosteric lobe (Muratcioglu et al., 2015) . Whether K-Ras molecules directly interact with one another when expressed at endogenous levels in cells-and whether this interaction is required for normal or oncogenic activity-has not been definitively established.
Based on their own analysis of K-Ras crystal structures, Ambrogio et al. (2018) predicted that the aspartic acid at position 154 (D154) of the a5 helix forms a salt bridge with arginine 161 (R161) of the opposing K-Ras molecule. They then determined experimentally that adding a positive charge to a5 by mutating aspartic acid to glutamine (D154Q) prevents dimerization while apparently not affecting the intrinsic exchange and hydrolysis activities of K-Ras. When combined with a codon 12 mutation (G12C or G12D) in K-Ras4B, D154Q prevented MAPK activation and cellular transformation, consistent with the prior demonstration that mutationally activated K-Ras must dimerize in order to promote oncogenic signaling (Nan et al., 2015) . Dimerization provides a reasonable molecular mechanism for the inhibitory activity of K-Ras WT: the WT (GDPbound) would form an ''inactive dimer'' by binding directly to the mutant (GTPbound) form ( Figure 1A ). This inactive dimer mechanism would also explain the common amplification of mutant K-Ras seen in cancers, since increasing the relative concentration of mutant would increase the likelihood of active mutant homodimers (Burgess et al., 2017) . Nevertheless, the previous NMR studies demonstrated that GDP-bound K-Ras4B forms weak and unstable homodimers in solution (Muratcioglu et al., 2015) . Consistent with this prior observation, the Ambrogio paper demonstrates that WT K-Ras4B requires mitogenic stimulation (i.e., GTP loading) to homodimerize. Although dimers between GDP-bound and GTP-bound GTPases occur in other instances-for example, for the Rag proteins (Sancak et al., 2008 )-it has not been established whether GDP-bound K-Ras can directly interact with the GTP-bound form. Ambrogio et al. (2018) demonstrate that K-Ras D154Q does not exhibit growth-suppressive activity and that K-Ras G12D/D154Q lacks oncogenic activity. While these observations can be explained by a loss of dimerization, they are also consistent with a general impairment in the ability of both WT and mutant K-Ras to engage downstream effectors or regulatory proteins ( Figure 1B ). There is some indication that mutant and WT forms of Ras have distinct effector preferences (Smith and Ikura, 2014); however, our knowledge of the structural and biochemical details of Ras interactions is incomplete. The biochemical assays routinely used for evaluating the core biochemical properties of Ras proteins utilize only the catalytic domains of guanine nucleotide exchange factors (GEFs) and GTPaseactivating proteins (GAPs) or the isolated Ras binding domains (RBDs) of effectors and therefore may not provide an entirely accurate picture of Ras biochemistry. A true understanding of how mutations in K-Ras affect its signaling properties will require a more comprehensive understanding of its molecular interactions with effectors or yet-to-be-identified interacting partners. A significant result in the Ambrogio paper is the demonstration that the R161E substitution is able to restore dimerization to the D154Q allele, presumably by restoring the salt bridge between the opposing K-Ras4B molecules in the dimer. It would be interesting in the future to test predictions based on this observation. For example, the dimer mechanism would predict that an R161E substitution should be able to restore oncogenic activity to K-Ras4B G12D/D154Q in cis and that K-Ras4B D154Q/R161E should be able to suppress the oncogenic activity of K-Ras4B G12D/D154Q/R161E in trans. Moreover, co-expression of K-Ras4B
and K-Ras4B G12D/D154Q should lead to transformation. In short, the ability of an R161E mutation to rescue a D154Q mutation in trans would provide concrete evidence that dimerization plays a key role in the functions of both WT and mutant K-Ras. Regardless of the mechanism by which D154Q inhibits the function of K-Ras, Ambrogio and colleagues validate two key therapeutic concepts. First, the balance of WT and mutant K-Ras in a cancer cell affects the level of MAPK signaling and therefore the sensitivity to inhibition of the pathway. This concept, initially established in leukemia (Burgess et al., 2017) , may allow for a priori identification of the subset of patients that are likely to respond to MAPK inhibitors. Second, the allosteric lobe of K-Ras can be targeted to inhibit is function. A key experimental validation of this therapeutic paradigm came in the form of a monobody targeting the a4-a5 interface, which, like the D154Q mutation, inhibits dimerization, signaling, and transformation (Spencer-Smith et al., 2017). In the end, this work brings us a step closer to precision medicine for K-Ras mutant cancers. Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R.R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) . Inhibition of RAS function through targeting an allosteric regulatory site. Nat. Chem. Biol. 13, 62-68.
Xu, J., Haigis, K.M., Firestone, A.J., McNerney, M.E., Li, Q., Davis, E., Chen, S.C., Nakitandwe, J., Downing, J., Jacks, T., et al. In this issue of Cell, Liu et al. (2018) report the birth of two healthy cloned macaque monkeys using fetal fibroblasts. By artificially enhancing the arsenal of epigenetic modifiers in the oocyte, the authors overcome the earliest roadblocks that take place during somatic cell nuclear transfer (SCNT).
Somatic cell nuclear transfer (SCNT) is a laboratory procedure used to clone animals. Although the steps involved may vary slightly among species, they have, for the most part, remained constant over the years. J.B. Gurdon, in 1962, first described the use of SCNT in vertebrates, showing that the nuclei of intestinal epithelial cells can be reprogrammed by the cytosol of an enucleated egg (Gurdon, 1962) . The ''new'' embryonic nuclei then developed into seemingly normal tadpoles. Some 35 years later came the first mammal ever cloned from an adult somatic cell, and what worked for Dolly the sheep in 1997 worked for about 22 other species cloned over the subsequent two decades (Rodriguez-Osorio et al., 2012) , but it did not work for one. Despite concerted efforts by many talented scientific teams around the world, no monkeys had been cloned from somatic cells.
In this issue of Cell, Liu et al. (2018) report the birth of healthy cloned macaque monkeys using fetal fibroblasts. This new milestone is the product of subtle refinements of decades-old cloning protocols and the use of epigenetic modifiers designed to overcome the earliest roadblocks that take place during SCNT (Figure 1 ).
We already knew the key basic elements necessary to clone mammals using somatic cells. The nuclei of Sertoli and cumulus cells, among the most suitable for cloning, should be in the G1 or G0 stage of the cell cycle when cloning from cultured somatic cells (Campbell et al., 1996) . The recipient oocyte must be at metaphase II with high levels of maturation-promoting factor, which in turn will induce both the rapid breakdown of the nuclear envelope and chromatin condensation. It is better to leave the reconstructed egg untouched for a few hours before triggering the resumption of the cell cycle. A premature release of intracellular calcium will hinder proper nuclear reprogramming and embryonic development. Egg activation is best achieved when intracellular calcium release mimics the same pattern triggered by sperm. The completion of the second meiotic division must be avoided to maintain normal ploidy. Finally, the sooner a cloned embryo is transferred to the uterus of a surrogate mother, the better the chances of producing a healthy clone.
Despite knowing all of these imperatives and despite decades of success using assisted reproductive technologies with macaques, implementing SCNT in monkeys proved harder to crack.
Until recently, we lacked the tools to understand how an oocyte could handle a somatic cell nucleus. The assumption was that a cloned embryo should be identical, both epigenetically and transcriptionally, to a one-cell fertilized embryo.
An early sign that cloned embryos not be considered equivalent to fertilized ones came from the pioneering work of Latham's group when, in 2002, they showed that a culture medium tailored to the metabolic needs of an early SCNT embryo was better than, but quite unlike, a conventional embryo medium (Chung et al., 2002) .
In general terms, during the first few hours after the onset of embryonic development, both fertilized and SCNT embryos undergo similar chromatin remodeling processes-i.e., global DNA demethylation and histone acetylation. Transcriptionally, though, they are very distinctive entities. Cloned embryos have a large number of genes-thousands-that remain unchanged before and after the somatic cell's introduction into the egg (Vassena et al., 2007) . These ''reprogrammingresistant genes'' carry the somatic cell's
